Published :
Tables : 52
Figures : 47
Category : Healthcare
No. of Pages : 233
Report Code : HC-1016
Infectious Disease Testing Market Overview: Infectious disease is caused by bacteria, virus and others and has a huge impact on healthcare systems of the countries. Infectious disease testing is the process of identification of causative organism for the primary diagnosis of diseases.Infectious diseases testing samples include blood, urine and other bodily fluids. Diagnosis is primary requisite for disease management, so infectious disease testing plays a very important role in primary healthcare settings. Increasing epidemics of infectious diseases require continuous testing and led robust growth of the market. Infectious diseases have a huge impact on healthcare systems due to high disease burden. Because of this, government bodies made it mandatory to run infectious disease testing across different domains. It created potential opportunities for infectious disease testing manufacturers and boosted the growth of the market. Further, changing regulatory policies to mandate the infectious disease testing for the general population fuelled the growth of the market. Along with these, technology has integrated the existing manual operations and led to the development of a fully automated process. Others factors like increasing awareness among the general population regarding the drastic effects of infectious diseases have boosted the robust growth of the infectious disease testing market. Developing economies made it mandatory for testing the general population regarding the infectious disease epidemics has boosted the growth of North America and Europe. North America infectious disease testing market accounts major share in the global market due to high penetration among the end users. It is followed by Europe and it witnessed a significant share due to stringent government policies. Asia Pacific and Latin America Infectious Disease Testing market is the most lucrative space for manufacturers due to high prevalence of infectious diseases. Rest of the world witnessed significant growth during the forecast period due to increasing awareness. Infectious disease testing manufacturers include Abbott Laboratories, Becton, Dickinson And Company, Biomérieux Sa, Bio-rad Laboratories, Danaher Corporation, Diasorin, Luminex, Meridian Bioscience, Quidel, Roche Diagnostics, Siemens Healthineers, Thermo Fisher Scientific, Trinity Biotech, ChemBio Diagnostics Systems, Orasure Technologies, SEEGENE, Co-Diagnostics, Genetic Signatures. Impact of COVID-19 on Infectious Disease Testing Market: Many diagnostic test manufacturers have initiated to develop and commercialize devices that facilitate testing procedures outside lab settings. These kits are capable of detecting COVID-19 proteins from the respiratory samples such as throat swab and sputum or through serum or blood. But WHO has recommended to use these point-of-care tests specifically in research settings. The rapid diagnostic testing is capable of detecting the presence of antigens of the novel coronavirus from a respiratory tract sample. Such advancements shall contribute in the market growth. Infectious Disease Testing Market Segmentation By Product & Service Assays, Kits, & Reagents Instruments Services & Software By Technology Immunodiagnostics Clinical Microbiology Polymerase Chain Reaction (Pcr) Isothermal Nucleic Acid Amplification Technology (Inaat) Dna Sequencing & Next-generation Sequencing (Ngs) Dna Microarray Other Technologies By Type of Testing Laboratory Testing POC Testing By Disease Type Hepatitis Human Immunodeficiency Virus (Hiv) Chlamydia Trachomatis Genital Infection And Gonorrhea (Ct/Ng) Hospital-acquired Infections (Hais) Human Papillomavirus (Hpv) Tuberculosis (Tb) Influenza Others By End User Hospital/Clinical Laboratories Reference Laboratories Physician Offices Academic/Research Institutes Others By Region Europe North America APAC Latin America Middle East and Africa Competitive Landscape: Tier 1 players- established companies in the market with a major market share Tier 2 players Emerging players which are growing rapidly New Entrants FutureWise Takeaways Growth prospects SWOT analysis Key trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the global infectious disease testing market on the basis of product & service, technology, by type of testing, by disease type, end user and region To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) To evaluate and forecast micro-markets and an overall market To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions Profiling of companies to evaluate their market shares, strategies, financials and core competencies Flexible Delivery Model: We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement The customization services offered are free of charge with purchase of any license of the report. You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Infectious disease is caused by bacteria, virus and others and has a huge impact on healthcare systems of the countries. Infectious disease testing is the process of identification of causative organism for the primary diagnosis of diseases.Infectious diseases testing samples include blood, urine and other bodily fluids. Diagnosis is primary requisite for disease management, so infectious disease testing plays a very important role in primary healthcare settings.
Increasing epidemics of infectious diseases require continuous testing and led robust growth of the market. Infectious diseases have a huge impact on healthcare systems due to high disease burden. Because of this, government bodies made it mandatory to run infectious disease testing across different domains. It created potential opportunities for infectious disease testing manufacturers and boosted the growth of the market. Further, changing regulatory policies to mandate the infectious disease testing for the general population fuelled the growth of the market. Along with these, technology has integrated the existing manual operations and led to the development of a fully automated process. Others factors like increasing awareness among the general population regarding the drastic effects of infectious diseases have boosted the robust growth of the infectious disease testing market.
Developing economies made it mandatory for testing the general population regarding the infectious disease epidemics has boosted the growth of North America and Europe. North America infectious disease testing market accounts major share in the global market due to high penetration among the end users. It is followed by Europe and it witnessed a significant share due to stringent government policies. Asia Pacific and Latin America Infectious Disease Testing market is the most lucrative space for manufacturers due to high prevalence of infectious diseases. Rest of the world witnessed significant growth during the forecast period due to increasing awareness.
Infectious disease testing manufacturers include Abbott Laboratories, Becton, Dickinson And Company, Biomérieux Sa, Bio-rad Laboratories, Danaher Corporation, Diasorin, Luminex, Meridian Bioscience, Quidel, Roche Diagnostics, Siemens Healthineers, Thermo Fisher Scientific, Trinity Biotech, ChemBio Diagnostics Systems, Orasure Technologies, SEEGENE, Co-Diagnostics, Genetic Signatures.
Impact of COVID-19 on Infectious Disease Testing Market:
Many diagnostic test manufacturers have initiated to develop and commercialize devices that facilitate testing procedures outside lab settings. These kits are capable of detecting COVID-19 proteins from the respiratory samples such as throat swab and sputum or through serum or blood. But WHO has recommended to use these point-of-care tests specifically in research settings. The rapid diagnostic testing is capable of detecting the presence of antigens of the novel coronavirus from a respiratory tract sample. Such advancements shall contribute in the market growth.
Infectious Disease Testing Market Segmentation
By Product & Service
By Technology
By Type of Testing
By Disease Type
By End User
By Region
Competitive Landscape:
FutureWise Takeaways
Objectives of the Study:
Flexible Delivery Model:
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Infectious Disease Testing Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Infectious Disease Testing Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Infectious Disease Testing Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Infectious Disease Testing Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Infectious Disease Testing Market, By Product & Service Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Assays, Kits, & Reagents 7.2. Instruments 7.3. Services & Software 8. Infectious Disease Testing Market, By Technology Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Immunodiagnostics 8.2. Clinical Microbiology 8.3. Polymerase Chain Reaction (Pcr) 8.4. Isothermal Nucleic Acid Amplification Technology (Inaat) 8.5. Dna Sequencing & Next-generation Sequencing (Ngs) 8.6. Dna Microarray 8.7. Other Technologies 9. Infectious Disease Testing Market, By Type of Testing Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Laboratory Testing 9.2. POC Testing 10. Infectious Disease Testing Market, By Disease Type Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Hepatitis 10.2. Human Immunodeficiency Virus (Hiv) 10.3. Chlamydia Trachomatis Genital Infection And Gonorrhea (Ct/Ng) 10.4. Hospital-acquired Infections (Hais) 10.5. Human Papillomavirus (Hpv) 10.6. Tuberculosis (Tb) 10.7. Influenza 10.8. Others 11. Infectious Disease Testing Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million) 11.1. Hospital/Clinical Laboratories 11.2. Reference Laboratories 11.3. Physician Offices 11.4. Academic/Research Institutes 11.5. Others 12. North America Infectious Disease Testing Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. U.S.A 12.2.2. Canada 12.2.3. Mexico 12.3. Market Size (USD Million) Forecast for North America 2022-2028 13. Latin America Infectious Disease Testing Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Brazil 13.2.2. Venezuela 13.2.3. Argentina 13.2.4. Rest of Latin America 13.3. Market Size (USD Million) Forecast for Latin America 2022-2028 14. Europe Infectious Disease Testing Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Germany 14.2.2. U.K 14.2.3. France 14.2.4. Italy 14.2.5. Spain 14.2.6. Russia 14.2.7. Poland 14.2.8. Rest of Europe 14.3. Market Size (USD Million) Forecast for Europe 2022-2028 15. Asia Pacific Infectious Disease Testing Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. Japan 15.2.2. China 15.2.3. India 15.2.4. Australia and New Zealand 15.2.5. ASEAN 15.2.6. Rest of Asia Pacific 15.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 16. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 16.1. Introduction 16.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 16.2.1. GCC 16.2.2. Israel 16.2.3. South Africa 16.2.4. Rest of MEA 16.3. Market Size (USD Million) Forecast for MEA 2022-2028 17. Market Share Analysis and Competitive Landscape 17.1. Global Landscape - Key Players, Revenue and Presence 17.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 17.3. Global Emerging Companies 17.4. North America - Market Share Analysis and Key Regional Players 17.5. Europe - Market Share Analysis and Key Regional Players 17.6. Asia Pacific - Market Share Analysis and Key Regional Players 17.7. Global Key Player - Growth Matrix 18. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 18.1. Abbott Laboratories 18.1.1. Company Overview 18.1.2. Product Portfolio 18.1.3. SWOT Analysis 18.1.4. Financial Overview 18.1.5. Strategic Overview 18.2. Becton, Dickinson And Company 18.2.1. Company Overview 18.2.2. Product Portfolio 18.2.3. SWOT Analysis 18.2.4. Financial Overview 18.2.5. Strategic Overview 18.3. Biomérieux Sa 18.3.1. Company Overview 18.3.2. Product Portfolio 18.3.3. SWOT Analysis 18.3.4. Financial Overview 18.3.5. Strategic Overview 18.4. Bio-rad Laboratories 18.4.1. Company Overview 18.4.2. Product Portfolio 18.4.3. SWOT Analysis 18.4.4. Financial Overview 18.4.5. Strategic Overview 18.5. Danaher Corporation 18.5.1. Company Overview 18.5.2. Product Portfolio 18.5.3. SWOT Analysis 18.5.4. Financial Overview 18.5.5. Strategic Overview 18.6. Diasorin 18.6.1. Company Overview 18.6.2. Product Portfolio 18.6.3. SWOT Analysis 18.6.4. Financial Overview 18.6.5. Strategic Overview 18.7. Luminex 18.7.1. Company Overview 18.7.2. Product Portfolio 18.7.3. SWOT Analysis 18.7.4. Financial Overview 18.7.5. Strategic Overview 18.8. Meridian Bioscience 18.8.1. Company Overview 18.8.2. Product Portfolio 18.8.3. SWOT Analysis 18.8.4. Financial Overview 18.8.5. Strategic Overview 18.9. Quidel 18.9.1. Company Overview 18.9.2. Product Portfolio 18.9.3. SWOT Analysis 18.9.4. Financial Overview 18.9.5. Strategic Overview 18.10. Roche Diagnostics 18.10.1. Company Overview 18.10.2. Product Portfolio 18.10.3. SWOT Analysis 18.10.4. Financial Overview 18.10.5. Strategic Overview 18.11. Siemens Healthineers 18.11.1. Company Overview 18.11.2. Product Portfolio 18.11.3. SWOT Analysis 18.11.4. Financial Overview 18.11.5. Strategic Overview 18.12. Thermo Fisher Scientific 18.12.1. Company Overview 18.12.2. Product Portfolio 18.12.3. SWOT Analysis 18.12.4. Financial Overview 18.12.5. Strategic Overview 18.13. Trinity Biotech 18.13.1. Company Overview 18.13.2. Product Portfolio 18.13.3. SWOT Analysis 18.13.4. Financial Overview 18.13.5. Strategic Overview 18.14. ChemBio Diagnostics Systems 18.14.1. Company Overview 18.14.2. Product Portfolio 18.14.3. SWOT Analysis 18.14.4. Financial Overview 18.14.5. Strategic Overview 18.15. Orasure Technologies 18.15.1. Company Overview 18.15.2. Product Portfolio 18.15.3. SWOT Analysis 18.15.4. Financial Overview 18.15.5. Strategic Overview 18.16. SEEGENE 18.16.1. Company Overview 18.16.2. Product Portfolio 18.16.3. SWOT Analysis 18.16.4. Financial Overview 18.16.5. Strategic Overview 18.17. Co-Diagnostics 18.17.1. Company Overview 18.17.2. Product Portfolio 18.17.3. SWOT Analysis 18.17.4. Financial Overview 18.17.5. Strategic Overview 18.18. Genetic Signatures 18.18.1. Company Overview 18.18.2. Product Portfolio 18.18.3. SWOT Analysis 18.18.4. Financial Overview 18.18.5. Strategic Overview 19. Pre and Post COVID-19 Impact 19.1. Positive influence on the healthcare industry 19.2. The financial disruption of the manufacturing sector 19.3. Impact of COVID-19 on emerging companies 19.4. Significant mandates in the healthcare regulations initiated by administrations 19.5. The overall economic slowdown of the developing and developed nations 20. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders
2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study
3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights
4. Infectious Disease Testing Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Infectious Disease Testing Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Infectious Disease Testing Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Infectious Disease Testing Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Infectious Disease Testing Market, By Product & Service Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Assays, Kits, & Reagents 7.2. Instruments 7.3. Services & Software
8. Infectious Disease Testing Market, By Technology Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Immunodiagnostics 8.2. Clinical Microbiology 8.3. Polymerase Chain Reaction (Pcr) 8.4. Isothermal Nucleic Acid Amplification Technology (Inaat) 8.5. Dna Sequencing & Next-generation Sequencing (Ngs) 8.6. Dna Microarray 8.7. Other Technologies
9. Infectious Disease Testing Market, By Type of Testing Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Laboratory Testing 9.2. POC Testing
10. Infectious Disease Testing Market, By Disease Type Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Hepatitis 10.2. Human Immunodeficiency Virus (Hiv) 10.3. Chlamydia Trachomatis Genital Infection And Gonorrhea (Ct/Ng) 10.4. Hospital-acquired Infections (Hais) 10.5. Human Papillomavirus (Hpv) 10.6. Tuberculosis (Tb) 10.7. Influenza 10.8. Others
11. Infectious Disease Testing Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million) 11.1. Hospital/Clinical Laboratories 11.2. Reference Laboratories 11.3. Physician Offices 11.4. Academic/Research Institutes 11.5. Others
12. North America Infectious Disease Testing Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. U.S.A 12.2.2. Canada 12.2.3. Mexico 12.3. Market Size (USD Million) Forecast for North America 2022-2028
13. Latin America Infectious Disease Testing Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Brazil 13.2.2. Venezuela 13.2.3. Argentina 13.2.4. Rest of Latin America 13.3. Market Size (USD Million) Forecast for Latin America 2022-2028
14. Europe Infectious Disease Testing Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Germany 14.2.2. U.K 14.2.3. France 14.2.4. Italy 14.2.5. Spain 14.2.6. Russia 14.2.7. Poland 14.2.8. Rest of Europe 14.3. Market Size (USD Million) Forecast for Europe 2022-2028
15. Asia Pacific Infectious Disease Testing Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. Japan 15.2.2. China 15.2.3. India 15.2.4. Australia and New Zealand 15.2.5. ASEAN 15.2.6. Rest of Asia Pacific 15.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
16. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 16.1. Introduction 16.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 16.2.1. GCC 16.2.2. Israel 16.2.3. South Africa 16.2.4. Rest of MEA 16.3. Market Size (USD Million) Forecast for MEA 2022-2028
17. Market Share Analysis and Competitive Landscape 17.1. Global Landscape - Key Players, Revenue and Presence 17.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 17.3. Global Emerging Companies 17.4. North America - Market Share Analysis and Key Regional Players 17.5. Europe - Market Share Analysis and Key Regional Players 17.6. Asia Pacific - Market Share Analysis and Key Regional Players 17.7. Global Key Player - Growth Matrix
18. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 18.1. Abbott Laboratories 18.1.1. Company Overview 18.1.2. Product Portfolio 18.1.3. SWOT Analysis 18.1.4. Financial Overview 18.1.5. Strategic Overview 18.2. Becton, Dickinson And Company 18.2.1. Company Overview 18.2.2. Product Portfolio 18.2.3. SWOT Analysis 18.2.4. Financial Overview 18.2.5. Strategic Overview 18.3. Biomérieux Sa 18.3.1. Company Overview 18.3.2. Product Portfolio 18.3.3. SWOT Analysis 18.3.4. Financial Overview 18.3.5. Strategic Overview 18.4. Bio-rad Laboratories 18.4.1. Company Overview 18.4.2. Product Portfolio 18.4.3. SWOT Analysis 18.4.4. Financial Overview 18.4.5. Strategic Overview 18.5. Danaher Corporation 18.5.1. Company Overview 18.5.2. Product Portfolio 18.5.3. SWOT Analysis 18.5.4. Financial Overview 18.5.5. Strategic Overview 18.6. Diasorin 18.6.1. Company Overview 18.6.2. Product Portfolio 18.6.3. SWOT Analysis 18.6.4. Financial Overview 18.6.5. Strategic Overview 18.7. Luminex 18.7.1. Company Overview 18.7.2. Product Portfolio 18.7.3. SWOT Analysis 18.7.4. Financial Overview 18.7.5. Strategic Overview 18.8. Meridian Bioscience 18.8.1. Company Overview 18.8.2. Product Portfolio 18.8.3. SWOT Analysis 18.8.4. Financial Overview 18.8.5. Strategic Overview 18.9. Quidel 18.9.1. Company Overview 18.9.2. Product Portfolio 18.9.3. SWOT Analysis 18.9.4. Financial Overview 18.9.5. Strategic Overview 18.10. Roche Diagnostics 18.10.1. Company Overview 18.10.2. Product Portfolio 18.10.3. SWOT Analysis 18.10.4. Financial Overview 18.10.5. Strategic Overview 18.11. Siemens Healthineers 18.11.1. Company Overview 18.11.2. Product Portfolio 18.11.3. SWOT Analysis 18.11.4. Financial Overview 18.11.5. Strategic Overview 18.12. Thermo Fisher Scientific 18.12.1. Company Overview 18.12.2. Product Portfolio 18.12.3. SWOT Analysis 18.12.4. Financial Overview 18.12.5. Strategic Overview 18.13. Trinity Biotech 18.13.1. Company Overview 18.13.2. Product Portfolio 18.13.3. SWOT Analysis 18.13.4. Financial Overview 18.13.5. Strategic Overview 18.14. ChemBio Diagnostics Systems 18.14.1. Company Overview 18.14.2. Product Portfolio 18.14.3. SWOT Analysis 18.14.4. Financial Overview 18.14.5. Strategic Overview 18.15. Orasure Technologies 18.15.1. Company Overview 18.15.2. Product Portfolio 18.15.3. SWOT Analysis 18.15.4. Financial Overview 18.15.5. Strategic Overview 18.16. SEEGENE 18.16.1. Company Overview 18.16.2. Product Portfolio 18.16.3. SWOT Analysis 18.16.4. Financial Overview 18.16.5. Strategic Overview 18.17. Co-Diagnostics 18.17.1. Company Overview 18.17.2. Product Portfolio 18.17.3. SWOT Analysis 18.17.4. Financial Overview 18.17.5. Strategic Overview 18.18. Genetic Signatures 18.18.1. Company Overview 18.18.2. Product Portfolio 18.18.3. SWOT Analysis 18.18.4. Financial Overview 18.18.5. Strategic Overview
19. Pre and Post COVID-19 Impact 19.1. Positive influence on the healthcare industry 19.2. The financial disruption of the manufacturing sector 19.3. Impact of COVID-19 on emerging companies 19.4. Significant mandates in the healthcare regulations initiated by administrations 19.5. The overall economic slowdown of the developing and developed nations
20. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics